Zacks Investment Research cut shares of Catalent Inc (NASDAQ:CTLT) from a buy rating to a hold rating in a research report report published on Friday.

According to Zacks, “Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment address the full diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. Catalent, Inc. is headquartered in Somerset, New Jersey. “

A number of other analysts have also recently issued reports on the company. Wells Fargo & Company reissued an outperform rating and set a $39.00 price objective (up previously from $30.00) on shares of Catalent in a research report on Thursday, August 31st. Bank of America Corporation reissued a buy rating and set a $40.00 price objective (up previously from $38.00) on shares of Catalent in a research report on Tuesday, August 29th. William Blair reissued an ourperform rating on shares of Catalent in a research report on Tuesday, August 29th. Jefferies Group LLC reissued a hold rating and set a $38.00 price objective (up previously from $35.00) on shares of Catalent in a research report on Tuesday, August 29th. Finally, J P Morgan Chase & Co reissued a buy rating and set a $40.00 price objective on shares of Catalent in a research report on Tuesday, August 29th. Four investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus price target of $36.22.

Shares of Catalent (NASDAQ:CTLT) opened at 40.66 on Friday. Catalent has a 52-week low of $21.83 and a 52-week high of $41.46. The stock has a market capitalization of $5.09 billion and a P/E ratio of 46.74. The firm’s 50-day moving average price is $35.64 and its 200-day moving average price is $32.75.

Catalent (NASDAQ:CTLT) last released its quarterly earnings data on Monday, August 28th. The company reported $0.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.57 by $0.08. The firm had revenue of $616.90 million during the quarter, compared to analysts’ expectations of $547.48 million. Catalent had a return on equity of 16.95% and a net margin of 4.88%. The business’s revenue for the quarter was up 15.9% on a year-over-year basis. During the same quarter last year, the firm earned $0.52 earnings per share. Equities analysts forecast that Catalent will post $1.60 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Catalent Inc (CTLT) Lowered to “Hold” at Zacks Investment Research” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright law. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/09/05/catalent-inc-ctlt-lowered-to-hold-at-zacks-investment-research.html.

In other Catalent news, SVP Christine Dolan sold 1,594 shares of the business’s stock in a transaction dated Tuesday, August 29th. The stock was sold at an average price of $38.75, for a total value of $61,767.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Large investors have recently made changes to their positions in the business. Flinton Capital Management LLC lifted its position in shares of Catalent by 17.7% in the first quarter. Flinton Capital Management LLC now owns 3,616 shares of the company’s stock worth $102,000 after buying an additional 544 shares during the last quarter. Acrospire Investment Management LLC lifted its position in shares of Catalent by 72.2% in the second quarter. Acrospire Investment Management LLC now owns 3,100 shares of the company’s stock worth $109,000 after buying an additional 1,300 shares during the last quarter. Quantbot Technologies LP lifted its position in shares of Catalent by 110.7% in the second quarter. Quantbot Technologies LP now owns 3,434 shares of the company’s stock worth $120,000 after buying an additional 1,804 shares during the last quarter. Meadow Creek Investment Management LLC lifted its position in shares of Catalent by 17.7% in the first quarter. Meadow Creek Investment Management LLC now owns 4,972 shares of the company’s stock worth $141,000 after buying an additional 748 shares during the last quarter. Finally, Acadian Asset Management LLC lifted its position in shares of Catalent by 115.7% in the first quarter. Acadian Asset Management LLC now owns 5,847 shares of the company’s stock worth $166,000 after buying an additional 3,136 shares during the last quarter.

Catalent Company Profile

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.

Get a free copy of the Zacks research report on Catalent (CTLT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Catalent (NASDAQ:CTLT)

Receive News & Stock Ratings for Catalent Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc and related stocks with our FREE daily email newsletter.